The US Food and Drug Administration (FDA) has accepted for review the regulatory application of a prefilled syringe presentation of Shingrix, GSK’s recombinant zoster vaccine for the prevention of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback